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During quiet breathing the inspiratory mus-
cles are active, whereas the expiratory muscles are
recruited only with increased ventilation, in-
creased load, and for coughing. In COPD, the in-
spiratory muscles face an elevated load for several
reasons (figure 1). Although airflow limitation is
more pronounced during expiration, the airway
resistance is increased during inspiration as well.
The inspiratory muscles also face an increased
elastic load because of a reduced dynamic compli-
ance, the lungs being stiffer than normal during
breathing. Finally, in cases of severe airflow limi-
tation, the time required to empty the lungs is far
greater than the time available for expiration. In
other words, the patient initiates the next inspira-
tion before reaching the normal end-expiratory
lung volume, i.e. functional residual capacity
(FRC). This increase in FRC due to incomplete
expiration is called “dynamic hyperinflation”. As
lung emptying is not fully terminated at end-expi-
ration, a residual positive pressure remains in the
airways which has been termed “intrinsic positive
end-expiratory pressure” (intrinsic PEEP or auto-
PEEP) [1, 2]. Before initiating inspiration, the pa-
tient has to generate a negative pressure equal to
the auto-PEEP in order to reverse the direction of
airflow. Thus, auto-PEEP represents an additional
load for the inspiratory muscles. In stable patients,
the auto-PEEP is only a few cm H2O, but it can
increase considerably if tidal volume or breathing
frequency increase, or if airflow limitation be-
comes more severe. For all these reasons, the pa-
tient with COPD must generate a higher than nor-
mal inspiratory pressure at each breath (Pbreath).
For a long time, the respiratory muscles have
been neglected being considered as part of a sim-
ple “bellows” mechanism by physiologists and pul-
monary physicians. Things have now markedly
changed and research has been particularly active
in this field over the past twenty years. The
scientific community recognised the central im-
portance of respiratory muscles in some diseases,
particularly in neuromuscular disorders and in
chronic obstructive pulmonary disease (COPD).
This brief review is intended to summarise the cur-
rent knowledge on respiratory muscle function in
COPD and and its relevance for clinical practice.
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Introduction
Respiratory muscle load
Figure 1
Mechanisms leading
to an imbalance
between respiratory
muscle load (Pbreath)
and capacity (Pmax) 
in COPD.
Respiratory muscle capacity
In COPD, lung hyperinflation is caused by
two mechanisms: static hyperinflation is due to loss
of the lungs elastic recoil (emphysema), and dy-
namic hyperinflation results from incomplete lung
emptying as mentioned above. The diaphragm,
which is a mobile structure, is profoundly affected
by lung hyperinflation, becoming shorter than
normal. Like all skeletal muscles, the diaphragm is
The inspiratory muscles in COPD are there-
fore characterised by an imbalance between load
and capacity, as reflected by an increased Pbreath/Pmax
ratio. If a skeletal muscle contracts above a certain
proportion of its maximal force, the contraction
cannot be maintained because of fatigue. In 1977,
Roussos and Macklem [9] tested the hypothesis of
diaphragmatic fatigue in humans. Healthy volun-
teers breathed mainly with their diaphragm against
different inspiratory resistances while their trans-
diaphragmatic pressure (Pdi) was measured with
oesophageal and gastric balloon-catheters. They
were able to breathe indefinitely when the ratio
Pdi/Pdi max was <0.4, but their endurance was lim-
ited when the ratio was set above this critical
threshold. Fatigue could be induced separately in
the diaphragm and in rib cage muscles according
to the breathing pattern, the critical threshold
being 0.6 when breathing mainly with rib cage
muscles [10, 11]. Thus, respiratory muscle fatigue
could easily be induced experimentally in volun-
teers submitted to breathing against resistances. It
was hypothesised that COPD patients, due to their
naturally increased Pbreath/Pmax ratio, develop respi-
ratory muscle fatigue during exacerbations leading
to ventilatory failure and hypercapnia. However, in
part because of methodological difficulties, it has
not been possible to prove overt respiratory mus-
cle fatigue in these circumstances. At present, it is
considered more likely that patients adopt by re-
flex a pattern of rapid shallow breathing to decrease
Pbreath. Thus, rapid shallow breathing would rep-
resent a way to avoid respiratory muscle fatigue, at
the expense of hypercapnia [12]. The mechanism
of this adaptive reflex is not known, but dyspnoea
may be involved because this sensation is clearly re-
lated to the Pbreath/Pmax ratio and to the neural drive
directed to inspiratory muscles [13, 14].
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Therapeutic options
Smoking cessation is beneficial at any stage of
COPD and should be a priority therapeutic goal
[15]. With regard to respiratory muscles, whatever
the actual role of fatigue, the imbalance between
load and capacity seems to be essential in the gen-
esis of dyspnoea and in the development of venti-
latory failure. The different therapeutic options
available to the clinician to correct this imbalance
are summarised here (figure 2).
Pharmacotherapy
Although airflow limitation is by definition lit-
tle influenced by drugs in COPD, this approach
should not be neglected. Inhaled bronchodilators,
anticholinergics and β2-agonists, are indicated for
any symptomatic patient. Even a small decrease in
airway resistance is beneficial and reduces the re-
quired inspiratory effort (Pbreath). Furthermore, it is
important to note that the inhalation of bron-
chodilators often has a larger effect on lung vol-
umes than on expiratory flows in COPD. Thus, a
marked fall of functional residual capacity may
occur with only a small or barely significant im-
provement in FEV1. Such a reduction of hyper-
inflation translates into an improvement of di-
aphragmatic strength (Pmax). Theophylline has a
limited bronchodilator effect and additionally has
a small inotropic effect on the diaphragm. How-
ever, this drug is not systematically recommended
in COPD because of its various adverse effects and
Consequences of load/capacity imbalance
governed by the length-tension relationship: at a
certain length, ie, at optimal length, the diaphrag-
matic muscles filaments of actin and myosin are in
an optimal relationship and the tension is maximal
for a given neural activation. If the muscle is work-
ing at a shorter length, the tension produced is
much less for the same level of neural activation
[3]. The reduced length of the diaphragm mainly
affects the part which is cranio-caudally oriented
and apposed to the lower rib cage, the so-called
“zone of apposition”. Because the diaphragm
works like a piston, a shorter zone of apposition
implies a shorter range of motion, independent of
the effect on maximal tension. Furthermore, the
zone of apposition may in part disappear if the di-
aphragm flattens, with the consequence that the
muscle fibers pull the ribs in an expiratory rather
than inspiratory direction [4].
In COPD, respiratory muscle capacity may be
impaired by additional mechanisms. COPD pa-
tients are frequently undernourished [5] and their
diaphragmatic muscle mass is reduced in even
greater proportion than their body weight [6]. Fur-
thermore, corticosteroids are still often used on a
long term basis in COPD despite their well known
adverse effects. Steroid myopathy may develop in
respiratory and peripheral muscles even at rela-
tively low doses [7, 8]. Electrolyte disturbances
affect skeletal muscle function and should be
checked for in acutely ill patients. 
These different mechanisms explain the re-
duced capacity of inspiratory muscles in COPD,
which translates into a lower maximal pressure
(Pmax).
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its narrow therapeutic range. During exacerba-
tions, oral corticosteroids have a favourable effect
on FEV1, and thereby likely on respiratory muscle
load/capacity imbalance. This translates into a re-
duced treatment failure rate and a shorter length of
hospitalisation. This effect is obtained with pred-
nisone 30 mg/day for 2 weeks [16]. Longer corti-
costeroid therapy should be avoided, in particular
because of the risk of steroid myopathy.
Lung volume reduction surgery (LVRS)
In case of severe hyperinflation due to emphy-
sema, preferentially of the heterogeneous type, re-
secting the most affected lung areas offers an in-
teresting palliation with reduction of hyperinfla-
tion, and improvement of spirometry and exercise
tolerance for a year or more. As can be expected,
the reduction of airflow limitation unloads the
inspiratory muscles, in particular via a marked
decrease in auto-PEEP [17]. By reducing hyperin-
flation LVRS helps restore a more physiological
length and shape of the diaphragm and thereby im-
proves its maximal strength [18]. The end result is
a significant reduction of the Pbreath/Pmax ratio [19]
and of the neural drive to the diaphragm [20, 21].
Ventilatory support
In patients with acute or chronic respiratory
failure, noninvasive mechanical ventilation via a
nasal or a facial mask immediately reduces the ac-
tivation and the work of inspiratory muscles and
provides relief of dyspnoea [22, 23]. The role of
long term non-invasive ventilation in COPD is still
uncertain, but a subgroup of severely hypercapnic
patients seems to benefit from this therapy. It has
been hypothesised that regular nocturnal ventila-
tory support could improve inspiratory muscle
strength, but this has not been consistently demon-
strated and alternative mechanisms probably play a
greater role.
Exercise training
Respiratory rehabilitation and its main compo-
nent exercise training are now accepted as a key ther-
apeutic approach to improve dyspnoea, quality of life
and exercise tolerance in patients with COPD [24,
25]. By improving aerobic capacity, general exercise
training reduces ventilatory needs and thereby de-
creases the load faced by inspiratory muscles [26].
Respiratory muscle training
In view of the reduced capacity of inspiratory
muscles in COPD, the idea of training respiratory
muscles specifically is appealing. Three main tech-
niques can be used: breathing against an inspiratory
resistance, breathing against an inspiratory thresh-
old load, and normocapnic hyperpnoea. Provided
that the stimulus is strong enough, there is no doubt
that respiratory muscle training increases inspiratory
muscle strength and endurance. However, after
more than 20 years of research, it has not been con-
sistently demonstrated that this is associated with
improvement in dyspnoea, quality of life and exer-
cise tolerance [27, 28]. Further studies are still
needed to better define both the methodology to be
used and the categories of patients susceptible to
benefit from respiratory muscle training.
Some recent studies may help explain why
training is less successful for respiratory muscles
than for peripheral muscles in COPD. Using
phrenic nerve stimulation, it was shown as expected
that the diaphragm of COPD patients generates
less pressure than that of normal subjects. How-
ever, considering the hyperinflation, it was found
that, at similar lung volumes, the diaphragm of
COPD patients was in fact able to generate slightly
higher than normal pressures [29]. This observa-
tion may be explained by an adaptive process to
chronic shortening of the diaphragm. Previous an-
imal studies had shown that the number and length
of diaphragm sarcomeres dropped in experimental
emphysema and this phenomenon was recently
demonstrated in biopsies of the diaphragm in pa-
tients with COPD [30]. Such an adaptation could
help maintain a normal strength despite a shorter
operational length. Another factor is the level of
neural activation of the diaphragm. In contrast to a
long held belief, electrophysiological studies show
that the diaphragm is more activated in patients
with COPD, even with hypercapnia, than in nor-
mal subjects [31]. If the diaphragm is chronically
contracting at a higher level, one may hypothesise
that it is submitted to a spontaneous training effect.
Two recent studies support this hypothesis. Di-
aphragmatic biopsies in patients with COPD
showed an increased density of mitochondria [30]
and a shift in muscle fibres with an increase in type
I (slow-twitch, oxidative) and a decrease in type II
(fast-twitch, glycolytic) fibres [32]. This pattern is
typical of endurance training and contrasts with op-
posite findings in peripheral muscles showing de-
conditioning in these patients. Thus, the relative
lack of beneficial effect of respiratory muscle train-
ing in COPD may be explained by their sponta-
neous training. The altered geometry of the dia-
phragm, with a shorter range of motion, also pre-
vents a gain in strength to be transformed into a
significant gain in volume displacement.
Figure 2
Therapeutic options
aiming at the correc-
tion of imbalance
between respiratory
muscle load (Pbreath)
and capacity (Pmax) 
in COPD.
COPD represents a model of respiratory mus-
cle dysfunction, mainly because of lung hyperinfla-
tion. Intensive research has confirmed the central
role of this dysfunction in the genesis of dyspnea
and respiratory failure. However, the perception of
this problem has slightly changed over the years.
First, the imbalance between load and capacity
seems to play a pivotal role in itself rather than via
the development of overt muscle fatigue. Second,
the apparent weakness of the diaphragm is essen-
tially due to lung hyperinflation. This muscle ap-
pears to be trained by chronic overload, in sharp
contrast with limb muscles which are typically de-
conditioned by sedentarity in these patients.
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